Cooperative Agreement UH3CA297234
Award Date 9/18/25
Completion Date 8/31/27
Dollars Obligated $195K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Michigan, USA
Similar Awards
- This $462,153 Project Grant was awarded on September 4, 2025 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Northern Michigan University (NMU). The grant will fund the development and utilization of a novel genetically encoded fluorescent biosensor, D2HGLO, to quantify intracellular concentrations of the oncometabolite d-2-hydroxyglutarate (d-2-HG) in cancer cells. This innovative tool will allow researchers to study the subcellular localization and...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $210,600 to the Regents of the University of Michigan to analytically validate and evaluate an H3K27M circulating tumor DNA (ctDNA) assay for monitoring diffuse midline glioma (DMG) patients. The project aims to establish the analytical performance characteristics of this high-sensitivity ctDNA assay as a CLIA-compliant laboratory developed test (LDT) and then...
- This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $266,736.00 to the Mayo Clinic for a project focused on "Assay Validation of Cell-Free DNA Amplified DNA Junctions for High Grade Glioma Monitoring." The award period runs from August 1, 2025 to July 31, 2026. The project aims to develop and validate new diagnostic tools and technologies to improve early detection, monitoring, and management of...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...
- This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...
- This Cooperative Agreement award for $310,185.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by New York University School of Medicine to analytically and clinically validate an Epic 900K V2 array-based methylation assay for predicting recurrence in stage II melanoma. The project aims to refine and validate a 13-probe signature that was previously found to accurately identify melanoma recurrence and mortality among stage II...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $677,998 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Medical College of Wisconsin, Inc. (MCW). The project aims to externally validate and integrate radiopathomic models developed using autopsy and biopsy samples to better delineate the true extent of glioma tumors and identify microscopic infiltrating tumor cells. The research will refine...
- The National Cancer Institute (NCI) awarded a $919,366 Project Grant to Nuvox Pharma, L.L.C., a small disadvantaged business located in Tucson, Arizona, under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394). The goal of this 2-year project, running from September 2025 to August 2027, is to evaluate liquid biopsy approaches to differentiate pseudoprogression from true disease progression in glioblastoma (GBM) patients treated with chemoradiation and an oxygen...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $690,637 to the Beckman Research Institute of the City of Hope to develop and validate a minimally invasive, highly sensitive, and cost-effective blood-based test for the early detection of pancreatic ductal adenocarcinoma (PDAC). The test will harness the potential of 5-methylcytosine (5MC) and 5-hydroxy methylcytosine (5HMC) DNA modifications on circulating...
- This $3,155,815 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research to develop advanced magnetic resonance imaging techniques for non-invasive measurement of glutamate metabolism in glioblastoma brain tumors. The primary awardee is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, which will leverage its expertise in medical research, imaging technologies, and...